Evidence map›Paper›PMID 33917394›Full record

ArticleCells2021

Penile Cancer-Derived Cells Molecularly Characterized as Models to Guide Targeted Therapies.

Hellen Kuasne, Luisa Matos do Canto, Mads Malik Aagaard, Juan Jose Moyano Muñoz, Camille De Jamblinne, Fabio Albuquerque Marchi, Cristovam Scapulatempo-Neto, Eliney Ferreira Faria, Ademar Lopes, Sébastien Carréno and 1 more

Open access · goldAbstract read
In one paragraph

Article in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

Hellen KuasneDepartment of Clinical Genetics, University Hospital of Southern Denmark-Vejle, Institute of Regional Health Research, University of Southern Denmark, 7100 Vejle, Denmark.
Luisa Matos do CantoDepartment of Clinical Genetics, University Hospital of Southern Denmark-Vejle, Institute of Regional Health Research, University of Southern Denmark, 7100 Vejle, Denmark.ORCID 0000-0001-9095-9431
Mads Malik AagaardDepartment of Clinical Genetics, University Hospital of Southern Denmark-Vejle, Institute of Regional Health Research, University of Southern Denmark, 7100 Vejle, Denmark.ORCID 0000-0003-4742-7047
Juan Jose Moyano MuñozInternational Research Center-A.C.Camargo Cancer Center, São Paulo 01508-010, Brazil.ORCID 0000-0002-1547-6357
Camille De JamblinneInstitute for Research in Immunology and Cancer and Département de Pathologie et de Biologie Cellulaire, Université de Montréal, Montréal, QC H3C 3J7, Canada.
Fabio Albuquerque MarchiInternational Research Center-A.C.Camargo Cancer Center, São Paulo 01508-010, Brazil.ORCID 0000-0001-5815-8423
Cristovam Scapulatempo-NetoMolecular Oncology Research Center, Barretos Cancer Hospital, Barretos 14784-400, Brazil.
Eliney Ferreira FariaMolecular Oncology Research Center, Barretos Cancer Hospital, Barretos 14784-400, Brazil.
Ademar LopesPelvic Surgery Department, A.C.Camargo Cancer Center, São Paulo 01508-010, Brazil.
Sébastien CarrénoInstitute for Research in Immunology and Cancer and Département de Pathologie et de Biologie Cellulaire, Université de Montréal, Montréal, QC H3C 3J7, Canada.
Silvia Regina RogattoDepartment of Clinical Genetics, University Hospital of Southern Denmark-Vejle, Institute of Regional Health Research, University of Southern Denmark, 7100 Vejle, Denmark.ORCID 0000-0003-4637-5687
University of Southern Denmark · DKAC Camargo Hospital · BRHospital de Câncer de Barretos · BRInstitute for Research in Immunology and Cancer · CA

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico 573589/08-9Fundação de Amparo à Pesquisa do Estado de São Paulo 2008/57887-9Fundação de Amparo à Pesquisa do Estado de São Paulo 2013/03667-6Fundação de Amparo à Pesquisa do Estado de São Paulo 2015/25373-0National Institute of Science and Technology in Oncogenomics FAPESP #2008/57887-9 and CNPq #573589/08-9Research Council of Lillebaelt Hospital, Denmark no nr.
6 · The paper itself

Abstract

Penile cancer (PeCa) is a common disease in poor and developing countries, showing high morbidity rates. Despite the recent progress in understanding the molecular events involved in PeCa, the lack of well-characterized in vitro models precludes new advances in anticancer drug development. Here we describe the establishment of five human primary penile cancer-derived cell cultures, including two epithelial and three cancer-associated fibroblast (CAF) cells. Using high-throughput genomic approaches, we found that the epithelial PeCa derived- cells recapitulate the molecular alterations of their primary tumors and present the same deregulated signaling pathways. The differentially expressed genes and proteins identified are components of key oncogenic pathways, including EGFR and PI3K/AKT/mTOR. We showed that epithelial PeCa derived cells presented a good response to cisplatin, a common therapeutic approach used in PeCa patients. The growth of a PeCa-derived cell overexpressing EGFR was inhibited by EGFR inhibitors (cetuximab, gefitinib, and erlotinib). We also identified CAF signature markers in three PeCa-derived cells with fibroblast-like morphology, indicating that those cells are suitable models for PeCa microenvironment studies. We thus demonstrate the utility of PeCa cell models to dissect mechanisms that promote penile carcinogenesis, which are useful models to evaluate therapeutic approaches for the disease.

Indexed as

Models, BiologicalMolecular Targeted TherapyAdultAgedAged, 80 and overCell Line, TumorCell MovementCell ProliferationCell ShapeGene Expression ProfilingGene Expression Regulation, NeoplasticGenome, HumanHumansMaleMiddle AgedNeoplasm InvasivenessNeoplasm ProteinsRNA, MessengerCAFscancer cell modelsEGFR inhibitorsgenomic profilepenile cancerprotein expressiontranslatomic profile

Identifiers

PMID33917394
PMCPMC8067406
OpenAlexW3144573330

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.